Search - tctmd.com

Displaying 81 - 100 of 233

Sort: Relevancy | Date

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

News Daily News

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

July 08, 2022

COVID-19: TCTMD’s Dispatch for May Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for May Week 3

May 16, 2022

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

News Daily News

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

Michael O'Riordan

April 27, 2022

COVID-19: TCTMD’s Dispatch for April Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for April Week 4

April 25, 2022

COVID-19: TCTMD’s Dispatch for April Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for April Week 2

April 11, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

April 02, 2022

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

News Daily News

Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials

Michael O'Riordan

March 23, 2022

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

News Features

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

March 14, 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

News Conference News ISC 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

February 11, 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

News Conference News ISC 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

February 10, 2022

Female-Specific Data Lacking for Myocardial Revascularization: SCAI

News Daily News

Female-Specific Data Lacking for Myocardial Revascularization: SCAI

February 08, 2022

Statins No Benefit to ICU-Admitted COVID-19 Patients: INSPIRATION-S

News Daily News

Statins No Benefit to ICU-Admitted COVID-19 Patients: INSPIRATION-S

January 07, 2022

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

Adapted D-Dimer Thresholds Safe, Efficient for Acute PE Diagnosis

News Daily News

Adapted D-Dimer Thresholds Safe, Efficient for Acute PE Diagnosis

December 16, 2021

TCTMD’s Top 10 Most Popular Stories for November 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

November 30, 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

News Conference News EACTS 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Michael O'Riordan

October 18, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

October 12, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.